Ruoqiao Chen

Ruoqiao Chen

Auto-generated profile, based on publicly available information

Ruoqiao Chen

Department of Pharmacology and Toxicology Michigan State University East Lansing Michigan USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
CMCheng Miao
Cheng Miao
ZDZehua Ding
Zehua Ding
JWJiaxing Wu
Jiaxing Wu
QAQi An
Qi An
YSYa Shu
Ya Shu
XCXiao-qian Chen
Xiao-qian Chen
The standard care of glioblastomas (GBM) confers limited survival benefit for patients due to the rapid tumor recurrence. Targeting tumor-associated macrophages/microglia via colony-stimulating factor 1 receptor (CSF-1R) inhibition is potentially effective in suppressing GBM recurrence. However, clinical trials of CSF-1R inhibitors failed to achieve their goal due to GBM resistance to anti-CSF-1R therapy. Here, we identified and verified key resistance mechanisms of anti-CSF-1R therapy by translatome profiling-combined analyses. To solve above problem, we have established a highly stable and refractory mouse G422 TN -GBM model, in which temozolomide (TMZ) is the most effective monotherapy but can only slightly extend animal survival. To identify effective resistance mechanism of anti-CSF1R therapy in GBM, we first apply the Translating ribosome affinity purification (TRAP) RNA-sequencing techniques in GBM tissues, which have previously used in neuroscience. TRAP-seq identified oxidative phosphorylation/glycolysis as anti-CSF1R therapy resistance mechanism, and it’s combined with Cancer Therapeutics Response Portal (CTRP) identified piperlongumine (PL) or vorinostat (SAHA) as targeting drugs. PL or SAHA enhanced PLX3397 efficacy by reversing oxidative phosphorylation/glycolysis dysregulation in vitro and in vivo. The triple combination of PLX3397, TMZ, and PL/SAHA significantly improved survival in G422 TN -GBM mice. In conclusion, targeting oxidative phosphorylation/glycolysis by PL or SAHA prominently improves therapeutic efficacy of PLX3397 + TMZ in GBM, which deserves priority for clinical trials. Our study also reveals that translatome profiling is efficient for uncovering drug-resistant targets.

1 April 2024 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
PDF file
SYShan-Ju Yeh
Shan-Ju Yeh
SPShreya Paithankar
Shreya Paithankar
RCRuoqiao Chen
Ruoqiao Chen
JXJing Xing
Jing Xing
MSMengying Sun
Mengying Sun
BCBin Chen
Bin Chen
Gene expression profiling of new or modified cell lines becomes routine today; however, obtaining comprehensive molecular characterization and cellular responses for a variety of cell lines, including those derived from underrepresented groups, is not trivial when resources are minimal. Using gene expression to predict other measurements has been actively explored; however, systematic investigation of its predictive power in various measurements has not been well studied. Here, we evaluated commonly used machine learning methods and presented TransCell, a two-step deep transfer learning framework that utilized the knowledge derived from pan-cancer tumor samples to predict molecular features and responses. Among these models, TransCell had the best performance in predicting metabolite, gene effect score (or genetic dependency), and drug sensitivity, and had comparable performance in predicting mutation, copy number variation, and protein expression. Notably, TransCell improved the performance by over 50% in drug sensitivity prediction and achieved a correlation of 0.7 in gene effect score prediction. Furthermore, predicted drug sensitivities revealed potential repurposing candidates for new 100 pediatric cancer cell lines, and predicted gene effect scores reflected BRAF resistance in melanoma cell lines. Together, we investigated the predictive power of gene expression in six molecular measurement types and developed a web portal (http://apps.octad.org/transcell/) that enables the prediction of 352,000 genomic and cellular response features solely from gene expression profiles.

1 May 2025 in Briefings in Bioinformatics
Verified
Journal Article
Open access
ZHZhiyue Tom Hu
Zhiyue Tom Hu
YYYaodong Yu
Yaodong Yu
RCRuoqiao Chen
Ruoqiao Chen
SYShan-Ju Yeh
Shan-Ju Yeh
BCBin Chen
Bin Chen
HHHaiyan Huang
Haiyan Huang
Pharmacogenomics studies are attracting an increasing amount of interest from researchers in precision medicine. The advances in high-throughput experiments and multiplexed approaches allow the large-scale quantification of drug sensitivities in molecularly characterized cancer cell lines (CCLs), resulting in a number of open drug sensitivity datasets for drug biomarker discovery. However, a significant inconsistency in drug sensitivity values among these datasets has been noted. Such inconsistency indicates the presence of substantial noise, subsequently hindering downstream analyses. To address the noise in drug sensitivity data, we introduce a robust and scalable deep learning framework, Residual Thresholded Deep Matrix Factorization (RT-DMF). This method takes a single drug sensitivity data matrix as its sole input and outputs a corrected and imputed matrix. Deep matrix factorization (DMF) excels at uncovering subtle patterns, due to its minimal reliance on data structure assumptions. This attribute significantly boosts DMF’s ability to identify complex hidden patterns among nuisance effects in the data, thereby facilitating the detection of signals that are therapeutically relevant. Furthermore, RT-DMF incorporates an iterative residual thresholding procedure, which plays a crucial role in retaining signals more likely to hold therapeutic importance. Validation using simulated datasets and real pharmacogenomics datasets demonstrates the effectiveness of our approach in correcting noise and imputing missing data in drug sensitivity datasets (open-source package available at https://github.com/tomwhoooo/rtdmf).

20 July 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
HJHai‐Feng Jiang
Hai‐Feng Jiang
PGPan‐Pan Gao
Pan‐Pan Gao
YDYu‐Wen Du
Yu‐Wen Du
LWLi‐Qin Wu
Li‐Qin Wu
EYEn‐Zhi Yin
En‐Zhi Yin
XCXiao Qian Chen
Xiao Qian Chen
Glioblastoma (GBM) is immunologically cold and responds poorly to immune‐based therapies owing to its highly heterogeneous and immunosuppressive tumor microenvironment (TME). However, strategies to achieve a cold‐to‐hot transition remain elusive, and suitable research models are still lacking. Here, TME profiling classifies our refractory G422 TN ‐GBM model as the TME Med (heterogeneous immune populations, “cold”) subtype of human GBM, which can be shifted toward the TME High (immune‐high, “hot”) subtype by inhibiting TGF‐β signaling. In the multi‐drug regimen, only αTGF‐β combining temozolomide chemoradiotherapy and αPD‐1 achieves immune‐cure (ICu, passing tumor rechallenge, 12.5%). ICu screening reveals a newly identified Csmd3 + microglial subset with innate immune memory potential, which likely initiates durable anti‐GBM immune memory and closely associates with effective GBM therapy and favorable prognosis. MG OE• Csmd3 , BV2 ( Csmd3 ‐overexpressed microglial BV2) elicit robust anti‐GBM effects and achieve a notably 100% tumor rechallenge success in G422 TN ‐GBM mice via promoting TME Med ‐to‐TME High remodeling. Taken together, our findings identify an immunologically cold TME Med GBM mouse model and provide a proof‐of‐concept for microglia‐based TME reprogramming and cell therapy in GBM.